{"analyses":[{"ciLowerLimit":"96.59","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"179.63","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"131.72"},{"ciLowerLimit":"172.14","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"331.93","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"239.03"},{"ciLowerLimit":"139.33","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"291.58","groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric means","paramValue":"201.56"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"14.98"},{"groupId":"OG001","spread":"38","value":"19.26"},{"groupId":"OG002","spread":"10","value":"13.65"},{"groupId":"OG003","spread":"40","value":"32.62"},{"groupId":"OG004","spread":"41","value":"12.78"},{"groupId":"OG005","spread":"67","value":"25.37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"8"}],"units":"Participants"}],"description":"Cmax is defined as the observed maximum plasma concentration post drug administration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"OG000","title":"Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone)"},{"description":"Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG001","title":"Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam"},{"description":"Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"OG002","title":"Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone)"},{"description":"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG003","title":"Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam"},{"description":"Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7.","id":"OG004","title":"RP2D Cohort: Crizotinib 250 mg (Midazolam Alone)"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.","id":"OG005","title":"RP2D Cohort: Crizotinib 250 mg + Midazolam"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration population of midazolam included all participants treated with midazolam (including Day -7 dose) who have at least 1 concentration of midazolam.","reportingStatus":"POSTED","timeFrame":"pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Day -7 (midazolam alone arm), pre-dose, 0.5, 1, 2, 4, 6, 8, 9, and 24 hours post dose on Cycle 2 Day 1 (midazolam with crizotinib arm)","title":"Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib","type":"PRIMARY","unitOfMeasure":"nanogram per milliliter"}